TNKASE (Tenecteplase)

TNKASE (Tenecteplase)

Vendor
HOFFMAN-LA ROCHE
Regular price
$3,849.99 USD
Sale price
$3,849.99 USD
Regular price
Sold out
Unit price
per 
Shipping calculated at checkout.

prescription refrigerated

What is this medication?

TNKASE (Tenecteplase)
Tissue plasminogen activator (tPA)

TNKASE (Tenecteplase) is a modified form of human tissue plasminogen activator (tPA) that binds to fibrin and converts plasminogen to plasmin to dissolve blood clots.  Tenecteplase is indicated for intravenous use in adults for the lysis of suspected occlusive coronary artery thrombi associated with evolving transmural myocardial infarction to reduce the mortality associated with acute myocardial infarction (AMI).

ALERT: WARNING
The most common complication encountered during TNKase therapy is internal and external bleeding. Internal bleeding, involving intracranial and retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts.  Superficial or surface bleeding, observed mainly at vascular puncture and access sites (e.g., venous cutdowns, arterial punctures) or sites of recent surgical intervention.  Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately and treated appropriately.

How does this medication work?

TNKASE (Tenecteplase) is a modified form of human tissue plasminogen activator (tPA) that binds to fibrin and converts plasminogen to plasmin.

How should I take this medication? 

IV: Intravenous single-bolus dose based on a 5-tiered weight-based dosing schedule to match the dose to the patient’s weight.

Note: Recommended dose should not exceed 50mg.

How to Take: Administer as a single IV bolus over 5 seconds. Avoid IM injections.

What should I watch for while using this medication? 

Before starting TNKASE (Tenecteplase) make sure your physician is aware of any allergies or medications you currently take.  The most common complication encountered during Tenecteplase therapy is bleeding.  Each patient being considered for therapy with Tenecteplase should be carefully evaluated according to risk versus benefit.  Tenecteplase therapy is contraindicated in cases of active internal bleeding, history of cerebrovascular accident, intracranial or intraspinal surgery, or trauma within 2 months, intracranial spasms, arteriovenous malformation, or aneurysm; known bleeding diathesis; and severe uncontrolled hypertension.

What if I miss a dose?

Since TNKASE (Tenecteplase) is used as a single dose, it does not have a daily dosing schedule.

How should I store this medication?

Store under refrigeration at 2°C to 8°C (36°F to 46°F) in the original carton and protect from direct sunlight.

What are the possible side effects of using this medication?

Bleeding, cardiogenic shock, arrhythmias, atrioventricular block, pulmonary edema, heart failure, cardiac arrest, recurrent myocardial ischemia, myocardial reinfarction, myocardial rupture, cardiac tamponade, pericarditis, pericardial effusion, mitral regurgitation, thrombosis, embolism, and electromechanical dissociation. 

Note this is not a complete list of side effects for TNKASE (Tenecteplase), only common ones.